NCT04432623: The BENeFiTS Trial in Beta Thalassemia Intermedia
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 36 planned
- Started
- 5 Oct 2020
- Primary completion
- 28 Feb 2026
- Arms
- Low dose, Middle dose, High dose 3 days per week, High dose 5 days per week, Sickle Cell Disease Arm
- Results
- None posted
- 16 Jun 2020: Trial registered
- 5 Oct 2020: Trial started